Boehringer Ingelheim· @Boehringer · X·· 2025-12-10精选AI 评分62
AI 导读
勃林格殷格翰宣布，中国国家药品监督管理局（NMPA）已批准其用于进展性肺纤维化（PPF）的新疗法。该公司称，在这一里程碑稀缺的领域，此次获批对PPF患者群体意味着积极的进展。
推荐理由
勃林格殷格翰披露其进展性肺纤维化疗法获NMPA批准，读者可了解该领域新增治疗选择的监管进展。
正文
#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). In a field where milestones are scarce, today signals meaningful momentum for the PPF community. Learn more: https://go.boehringer.com/amhKM
来源：Boehringer Ingelheim · x.com